Skip to main content
SpringerLink
Log in

Rizatriptan worth it in Canada for moderate-to-severe migraine

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rizatriptan worth it in Canada for moderate-to-severe migraine. Pharmacoecon. Outcomes News 485, 7 (2005). https://doi.org/10.2165/00151234-200504850-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200504850-00014

Keywords

Search

Navigation